Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Variant receptors challenge treatment strategies for prostate cancer

Publish date:: February 9, 2021

Key clinical point: Androgen receptors and the splice variant AR-V7 both regulated subsets of target genes and also induced alternative splicing of mRNAs in prostate cancer cells.

Major finding: A novel exon linked to exon 4 notably increased the induction of the PGAP2 gene by the androgen receptor variant known as AR-V7 to a 50-fold induction.

Study details: The data come from an examination of two endogenous genes, PGAP2 and TPD52, to determine their impact on splicing in prostate cancer cells using cell lines.

Disclosures: The study was supported by DAMD W81XWH-17-1-0236 and CPRIT RP150648 as well as by The Cancer Prevention Institute of Texas, the National Institutes of Health, and the National Institute of Environmental Health Sciences.

Citation:

Rana M et al. Sci Rep. 2021 Jan 14. doi: 10.1038/s41598-021-81164-0.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in Prostate Cancer

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,